Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

Objective Interleukin 13 (IL-13) is thought to play a key role as an effector cytokine in UC. Anrukinzumab, a humanised antibody that inhibits human IL-13, was evaluated for the treatment of UC. Design In a multicentre, randomised, double-blind, placebo-controlled study, patients with active UC (May...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 2015-06, Vol.64 (6), p.894-900
Hauptverfasser:	Reinisch, Walter, Panés, Julián, Khurana, Sunil, Toth, Gabor, Hua, Fei, Comer, Gail M, Hinz, Michelle, Page, Karen, O'Toole, Margot, Moorehead, Tara McDonnell, Zhu, Hua, Sun, YanHui, Cataldi, Fabio
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Adolescent Adult Aged Analysis of Variance Antibodies, Monoclonal, Humanized - pharmacokinetics Antibodies, Monoclonal, Humanized - therapeutic use Biomarkers Biomarkers - blood Biopsy Clinical medicine Colitis, Ulcerative - blood Colitis, Ulcerative - drug therapy Colitis, Ulcerative - pathology Colon - pathology Crohn's disease Cytokines Dose-Response Relationship, Drug Double-Blind Method Endoscopy Eosinophils - cytology Eosinophils - drug effects Feces - chemistry Female Humans Immunosuppressive Agents - therapeutic use Interleukin-13 - antagonists & inhibitors Interleukin-13 - blood Leukocyte Count Leukocyte L1 Antigen Complex - analysis Male Middle Aged Molecular weight Remission Induction Rodents TNF inhibitors Treatment Outcome Tumor necrosis factor-TNF Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective Interleukin 13 (IL-13) is thought to play a key role as an effector cytokine in UC. Anrukinzumab, a humanised antibody that inhibits human IL-13, was evaluated for the treatment of UC. Design In a multicentre, randomised, double-blind, placebo-controlled study, patients with active UC (Mayo score ≥4 and
ISSN:	0017-5749 1468-3288
DOI:	10.1136/gutjnl-2014-308337